X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs AUROBINDO PHARMA - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD AUROBINDO PHARMA ORCHID PHARMA LTD/
AUROBINDO PHARMA
 
P/E (TTM) x -0.1 18.8 - View Chart
P/BV x 0.1 3.8 3.4% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 ORCHID PHARMA LTD   AUROBINDO PHARMA
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
AUROBINDO PHARMA
Mar-18
ORCHID PHARMA LTD/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs194809 24.0%   
Low Rs35504 6.9%   
Sales per share (Unadj.) Rs276.5281.1 98.4%  
Earnings per share (Unadj.) Rs-79.241.4 -191.5%  
Cash flow per share (Unadj.) Rs-43.550.9 -85.4%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs53.9199.4 27.1%  
Shares outstanding (eoy) m70.45585.88 12.0%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.42.3 17.7%   
Avg P/E ratio x-1.415.9 -9.1%  
P/CF ratio (eoy) x-2.612.9 -20.4%  
Price / Book Value ratio x2.13.3 64.5%  
Dividend payout %06.0 0.0%   
Avg Mkt Cap Rs m8,067384,630 2.1%   
No. of employees `0002.817.3 16.2%   
Total wages/salary Rs m2,52721,308 11.9%   
Avg. sales/employee Rs Th6,956.19,500.7 73.2%   
Avg. wages/employee Rs Th902.51,229.4 73.4%   
Avg. net profit/employee Rs Th-1,993.01,397.9 -142.6%   
INCOME DATA
Net Sales Rs m19,477164,666 11.8%  
Other income Rs m4071,020 39.9%   
Total revenues Rs m19,884165,686 12.0%   
Gross profit Rs m1,10337,718 2.9%  
Depreciation Rs m2,5195,580 45.1%   
Interest Rs m5,227777 672.5%   
Profit before tax Rs m-6,23632,380 -19.3%   
Minority Interest Rs m2031 62.7%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1258,183 -1.5%   
Profit after tax Rs m-5,58024,229 -23.0%  
Gross profit margin %5.722.9 24.7%  
Effective tax rate %2.025.3 7.9%   
Net profit margin %-28.714.7 -194.7%  
BALANCE SHEET DATA
Current assets Rs m11,014121,878 9.0%   
Current liabilities Rs m32,06086,806 36.9%   
Net working cap to sales %-108.121.3 -507.3%  
Current ratio x0.31.4 24.5%  
Inventory Days Days95130 73.1%  
Debtors Days Days3468 49.1%  
Net fixed assets Rs m29,44081,037 36.3%   
Share capital Rs m705586 120.2%   
"Free" reserves Rs m2,043116,218 1.8%   
Net worth Rs m3,800116,804 3.3%   
Long term debt Rs m9,0184,512 199.9%   
Total assets Rs m46,510211,052 22.0%  
Interest coverage x-0.242.7 -0.5%   
Debt to equity ratio x2.40 6,143.6%  
Sales to assets ratio x0.40.8 53.7%   
Return on assets %-0.811.8 -6.4%  
Return on equity %-146.920.7 -708.0%  
Return on capital %-3.727.4 -13.7%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51380,727 9.3%   
Fx outflow Rs m5,64934,700 16.3%   
Net fx Rs m1,86546,027 4.1%   
CASH FLOW
From Operations Rs m1,68219,548 8.6%  
From Investments Rs m-9,860-19,570 50.4%  
From Financial Activity Rs m6,6448,642 76.9%  
Net Cashflow Rs m-1,5358,922 -17.2%  

Share Holding

Indian Promoters % 32.3 54.1 59.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 8.0 57.9%  
FIIs % 3.3 27.7 11.9%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 10.2 542.2%  
Shareholders   84,811 69,601 121.9%  
Pledged promoter(s) holding % 54.9 8.6 641.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   CIPLA  PFIZER  ALKEM LABORATORIES  SUN PHARMA  SANOFI INDIA  

Compare ORCHID PHARMA LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 383 Points Lower; Realty and Auto Stocks Drag(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Oct 3, 2018 | Updated on Oct 3, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)

Oct 5, 2018

Find companies with long term durable moats, which are correcting with the current broader market sell-off.

Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)

Oct 5, 2018

Ajit Dayal on the crisis in the market and in the mutual fund industry.

This Market Crash could be the Biggest Wealth Creating Opportunity Since 2008(Profit Hunter)

Oct 8, 2018

While widespread fear is the friend of a value investor, serving up bargain purchases; personal fear is an investor's biggest enemy.

IPO Market Feels the Heat of the Market Crash(Sector Info)

Oct 12, 2018

The sentiments in primary market have also deteriorated amid the stock market correction. Most listed IPOs of 2018 are trading below their issue price.

Are These Deep Corrections a Buying Signal?(Chart Of The Day)

Oct 5, 2018

The correction has bought many good companies to reasonable valuations. Go against the wisdom of crowd and Buy.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Oct 17, 2018 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD - DR. DATSONS LABS COMPARISON

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS